Playback speed
10 seconds
Nivo/Ipi Rx of Choice for Adv. NSCLC, PD-L1 Under 1%, High TMB? New CheckMate 227 Data
By
Beacon Medical Interchange
FEATURING
Jack West
By
Beacon Medical Interchange
FEATURING
Jack West
60 views
October 29, 2018
Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC ...
read more ↘ & tumor PD-L1 Under 1% that suggests potential utility of the nivolumab/ipilimumab (nivo/ipi) combination in patients with low PD-L1 and high tumor mutation burden (TMB).
↖ read less
read more ↘ & tumor PD-L1 Under 1% that suggests potential utility of the nivolumab/ipilimumab (nivo/ipi) combination in patients with low PD-L1 and high tumor mutation burden (TMB).
↖ read less
Comments 0
Login to view comments.
Click here to Login
Lung